Breast Cancer
Conference Coverage
Novel immune activator boosts immunotherapy benefit in TNBC
From the Journals
Excess cancer deaths predicted as care is disrupted by COVID-19
Conference Coverage
Antitumor treatment may increase risk of severe events in COVID-19 patients
Conference Coverage
EMBRACA shows no overall survival benefit with talazoparib
Talazoparib did not confer an overall survival benefit over chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast...
Conference Coverage
Novel combo boosts response in HER2-negative breast cancer
Guidelines
ESMO gets creative with guidelines for breast cancer care in the COVID-19 era
News from the FDA/CDC
FDA OKs new drug for triple-negative breast cancer
Sacituzumab govitecan-hziy (Trodelvy) is now approved for adults with metastatic triple-negative breast cancer who received at least two prior...
From the Journals
‘Eye-opening’: Cognitive decline with endocrine therapy for breast cancer
From the Journals
‘Encouraging’ results with pre-op therapy for DCIS
News from the FDA/CDC
FDA approves first new breast cancer drug with international group
Guidelines
Breast-conserving surgery deemed okay in high-risk hereditary breast cancers
The presence of a germline BRCA1/2 mutation shouldn’t preclude breast-conserving therapy as long as the patient is otherwise eligible, new...